You are viewing: Rest Of GCC Countries Oral Proteins & Peptides Market analysis

The Rest Of GCC Countries Oral Proteins & Peptides Market was valued at $2.3 Million in 2025 and projected to reach to $4.24 Million by 2030, representing a compound annual growth rate of 13.0%. Rest Of GCC Countries' oral proteins & peptides market is positioned for steady expansion, driven by increasing healthcare modernization and pharmaceutical sector development.

Rest Of GCC Countries Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of GCC Countries Oral Proteins & Peptides Market Trends and Insights

  • Rest Of GCC Countries represents a developing segment within the broader GCC region, driven by increasing healthcare investments and rising demand for advanced pharmaceutical formulations.
  • The market in Rest Of GCC Countries is characterized by growing adoption of oral peptide therapeutics, supported by improving healthcare infrastructure and regulatory frameworks across the region. Rest Of GCC Countries is witnessing accelerating market penetration as pharmaceutical companies expand their portfolios to address chronic disease management and metabolic disorders.
  • The 13.0% compound annual growth rate reflects Rest Of GCC Countries' emerging position in the oral proteins & peptides sector, with significant potential for innovation and market development through 2030.
  • Rest Of GCC Countries' market trajectory is supported by increasing healthcare spending, rising patient awareness, and growing partnerships between local and international pharmaceutical manufacturers..

Key Market Statistics

  • CAGR (2025-2030) 13.0% CAGR
  • Market Size, 2025 ~USD 2.3 Million
  • Forecast, 2030 ~USD 4.24 Million
  • Country Rest Of GCC Countries

Rest Of GCC Countries Oral Proteins & Peptides Market Overview

Market Valuation Growth :

Rest Of GCC Countries' oral proteins & peptides market is valued at USD 2.3 million in 2025, with a projected CAGR of 13% through 2030, reaching USD 4.24 million by forecast end.

Healthcare Investment Surge :

Increasing government and private healthcare investments across Rest Of GCC Countries are driving adoption of advanced pharmaceutical formulations and oral protein therapies.

Emerging Market Potential :

Rest Of GCC Countries represents a developing yet high-potential segment within the broader GCC region, with growing pharmaceutical infrastructure and regulatory frameworks supporting market expansion.

Regional Demand Drivers :

Rising prevalence of chronic diseases, improved healthcare accessibility, and growing awareness of peptide-based therapeutics are key growth catalysts in Rest Of GCC Countries.

Rest Of GCC Countries Oral Proteins & Peptides Market Dynamics

  • The region's growing middle class and rising healthcare expenditure create favorable conditions for advanced therapeutic adoption.
  • Government initiatives to enhance healthcare infrastructure and pharmaceutical manufacturing capabilities are expected to accelerate market penetration over the forecast period. The 13% CAGR reflects Rest Of GCC Countries' emerging status within the GCC pharmaceutical landscape.
  • While growing slower than the global 22.1% rate, the market demonstrates resilience and consistent demand growth.
  • Strategic partnerships with international pharmaceutical companies and local manufacturing investments will likely enhance market accessibility and drive competitive pricing, further supporting market expansion through 2030..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Rest Of GCC Countries oral proteins & peptides market is valued at USD 2.3 million in 2025, growing at a 13.0% CAGR through 2030.
    • Rest Of GCC Countries is projected to reach USD 4.24 million by 2030, reflecting strong regional healthcare sector expansion.
    • Rest Of GCC Countries benefits from improving regulatory frameworks and increased pharmaceutical company investments in oral peptide formulations.
    • Rest Of GCC Countries market growth is driven by rising chronic disease prevalence and expanding healthcare infrastructure across the region.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Rest Of GCC Countries Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Manufacturers : Identify market entry opportunities and localized product development strategies for Rest Of GCC Countries' growing oral proteins & peptides segment.
    • Healthcare Investors : Assess investment potential and ROI projections for pharmaceutical ventures and healthcare infrastructure projects in Rest Of GCC Countries.
    • Market Strategists : Develop regional expansion plans and competitive strategies leveraging Rest Of GCC Countries-specific market data and growth forecasts.
    • Regulatory & Policy Advisors : Understand Rest Of GCC Countries' pharmaceutical regulatory landscape and healthcare policy drivers shaping oral peptide market development.
    • Distribution & Supply Chain Partners : Optimize distribution networks and supply chain strategies for Rest Of GCC Countries' emerging oral proteins market with localized demand insights.

    Key Companies in the Rest Of GCC Countries Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market-Specific Sizing Data : Access precise valuation metrics for Rest Of GCC Countries with 2025 baseline (USD 2.3M) and 2030 forecasts (USD 4.24M), enabling accurate budget allocation and investment planning.
    • Regional Growth Trajectory : Understand Rest Of GCC Countries' distinct 13% CAGR performance relative to global 22.1% growth, identifying unique market dynamics and localized expansion opportunities.
    • Healthcare Investment Insights : Gain intelligence on Rest Of GCC Countries' healthcare infrastructure development, regulatory environment, and pharmaceutical sector investments driving oral protein adoption.
    • Competitive Positioning Strategy : Develop targeted market entry and expansion strategies specific to Rest Of GCC Countries' emerging pharmaceutical landscape and healthcare stakeholder ecosystem.
    • Risk & Opportunity Assessment : Evaluate market maturity, growth catalysts, and barriers to entry unique to Rest Of GCC Countries for informed decision-making and resource optimization.

    Frequently asked questions

    What is the current market size of oral proteins & peptides in Rest Of GCC Countries?

    Rest Of GCC Countries oral proteins & peptides market is valued at USD 2.3 million in 2025.

    What is the projected market size for Rest Of GCC Countries by 2030?

    Rest Of GCC Countries is projected to reach USD 4.24 million by 2030, representing significant growth over the forecast period.

    What is the CAGR for the oral proteins & peptides market in Rest Of GCC Countries?

    Rest Of GCC Countries market is growing at a compound annual growth rate of 13.0% from 2025 to 2030.

    What factors are driving growth in Rest Of GCC Countries?

    Rest Of GCC Countries growth is driven by increasing healthcare investments, rising chronic disease prevalence, improving regulatory frameworks, and expanding pharmaceutical company presence in the region.

    How does Rest Of GCC Countries compare to the broader GCC market?

    Rest Of GCC Countries represents a developing segment within the GCC region with a 13.0% CAGR, contributing to the overall regional market expansion in oral proteins & peptides.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status